|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- August 6, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Addrenex Pharmaceuticals, of Research Triangle Park, N.C., has entered into an exclusive partnership in which it licensed the right to manufacture, market and sell its lead product, Clonicel, in Korea to Dream Pharma Ltd., of London. Clonicel is being developed for both the treatment of hypertension and attention deficit hyperactivity disorder. Financial terms were not disclosed.
Adventrx Pharmaceuticals Inc., of San Diego, said it intends to submit a new drug application for ANX-530 (vinorelbine emulsion) by the end of the year. The company said it successfully completed the final manufacturing activities required for the NDA submission, which were restarted ...
Related newspaper, magazine, and journal articles:
|
|
Article: Canadian Bio Med Systems, Inc., today ...
PR Newswire;
September 9, 2008 ;
700+ words
... ... PRNewswire-FirstCall/ -- Canadian Bio Med Systems Inc., a wholly owned subsidiary ... currently under development by Canadian Bio Med Systems, Inc. with their partner Ocular ... icbs.ca/; Source: Canadian Bio Med Systems Inc.
|
|